{"bill": {"#text": "\n\t", "form": {"current-chamber": {"#tail": "\n\t\t", "#text": "IN THE HOUSE OF REPRESENTATIVES"}, "#text": "\n\t\t", "congress": {"#tail": "\n\t\t", "#text": "113th CONGRESS"}, "#tail": "\n\t", "legis-num": {"#tail": "\n\t\t", "#text": "H. R. 3019"}, "official-title": {"#tail": "\n\t", "#text": "To amend chapter V of the Federal Food, Drug, and\n\t\t  Cosmetic Act to enhance the requirements for pharmacies that compound drug\n\t\t  products."}, "session": {"#tail": "\n\t\t", "#text": "1st Session"}, "distribution-code": {"#tail": "\n\t\t", "@display": "yes", "#text": "I"}, "action": {"action-date": {"#tail": "\n\t\t\t", "@date": "20130802", "#text": "August 2, 2013"}, "#tail": "\n\t\t", "action-desc": {"#tail": "\n\t\t", "#text": "\n        ", "committee-name": {"#tail": "\n      ", "@committee-id": "HIF00", "#text": "Committee\n\t\t\t on Energy and Commerce"}, "sponsor": {"#tail": " (for\n\t\t\t herself, ", "#text": "Ms. DeLauro", "@name-id": "D000216"}, "cosponsor": [{"#tail": ",\n\t\t\t ", "#text": "Mrs. Lowey", "@name-id": "L000480"}, {"#tail": ",\n\t\t\t ", "#text": "Mr. Conyers", "@name-id": "C000714"}, {"#tail": ", and\n\t\t\t ", "#text": "Mr. Honda", "@name-id": "H001034"}, {"#tail": ") introduced the following\n\t\t\t bill; which was referred to the ", "#text": "Mr. Ellison", "@name-id": "E000288"}]}, "#text": "\n\t\t\t"}, "legis-type": {"#tail": "\n\t\t", "#text": "A BILL"}}, "@bill-stage": "Introduced-in-House", "@bill-type": "olc", "@dms-id": "H39173ED51DD04B14A56277308CC901C8", "@public-private": "public", "legis-body": {"#tail": "\n", "@style": "OLC", "section": [{"@section-type": "section-one", "#tail": "\n    ", "text": {"#tail": "\n\t\t", "quote": [{"short-title": {"#tail": "\n        ", "#text": "Supporting Access to Formulated and\n\t\t\t Effective Compounded Drugs Act of 2013"}, "#tail": " or the\n\t\t\t ", "#text": "\n          "}, {"short-title": {"#tail": "\n        ", "#text": "S.A.F.E. Compounded Drugs Act of\n\t\t\t 2013"}, "#tail": ".", "#text": "\n          "}], "#text": "This Act may be cited as the\n\t\t\t ", "@display-inline": "no-display-inline"}, "enum": {"#tail": "\n      ", "#text": "1."}, "header": {"#tail": "\n      ", "#text": "Short title"}, "#text": "\n      ", "@id": "HA41F3B8BE8524902924E06EDA1D43770"}, {"#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "2."}, "header": {"#tail": "\n\t\t\t", "#text": "Enhanced\n\t\t\t requirements for compounded drugs"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended\u2014", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 503A of the\n\t\t\t Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 353a", "@value": "usc/21/353a"}, "@parsable-cite": "usc/21/353a", "#text": "\n              ", "@legal-doc": "usc"}}, "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "In\n\t\t\t general"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by inserting ", "@entity-type": "act", "#text": "subsection\n\t\t\t (a)(1)(A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:A"}, "#text": "in ", "quote": [{"#tail": " after ", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " under\n\t\t\t ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " (or is subject to the exception under ", "@entity-type": "act", "#text": "subsection (b)(6)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:6"}, {"#tail": ")", "@entity-type": "act", "#text": "subsection\n\t\t\t (b)(6)(C)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:6/sp:C"}], "#text": "that is registered with the "}, {"#tail": ";", "#text": "State licensed pharmacy"}]}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "HE885E98B883449839C5803D338D96EC6", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "act", "#text": "subsection\n\t\t\t (b)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b"}, "#text": "in "}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "#text": "\n          ", "@id": "H435AB44DB7AB41C6BAFC3C34A3DD2AB7", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by inserting ", "@entity-type": "act", "#text": "paragraph\n\t\t\t (1)(A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1/sp:A"}, "#text": "in ", "quote": [{"#tail": " after ", "#text": "(meaning not more than 5 percent of the total\n\t\t\t quantity of drugs products compounded by the pharmacist or physician in any 30\n\t\t\t day period)"}, {"#tail": ";", "#text": "limited quantities"}]}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H3CAF5118277D46849E59F2ACA8443DCF", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by striking ", "@entity-type": "act", "#text": "paragraph\n\t\t\t (1)(C)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1/sp:C"}, "#text": "in ", "quote": {"#tail": " at the end;", "#text": "and"}}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "#text": "\n            ", "@id": "H6D0D3B2D98F3434FA9E4B917651F7A22", "@commented": "no"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", by striking ", "@entity-type": "act", "#text": "paragraph\n\t\t\t (1)(D)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1/sp:D"}, "#text": "in ", "quote": {"#tail": ";", "#text": "regularly or in inordinate amounts (as defined by\n\t\t\t the Secretary)"}}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "@id": "HF460DAF1CB82467CADDD633A82B85660", "#text": "\n            "}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the following:", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:1"}, "#text": "by adding at the\n\t\t\t end of "}, "enum": {"#tail": "\n            ", "#text": "(D)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": ";\n\t\t\t\tand"}, "#tail": "\n\t\t\t\t\t", "@id": "HAA3113AF7A4E4EEB9B2E2B653029F3AB", "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t\t", "subparagraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ";\n\t\t\t\tand", "@entity-type": "act", "#text": "subsection (h)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:h"}], "#text": "does not compound a drug product that\n\t\t\t\tappears on the list promulgated by the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                ", "#text": "(E)"}, "@id": "HAC43D667FD244B95A31AA0CD4FCB7A12", "#text": "\n                "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (i)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:i"}, "#text": "does not compound\n\t\t\t\ta drug product in violation of the minimum standards promulgated under\n\t\t\t\t"}, "enum": {"#tail": "\n                ", "#text": "(F)"}, "#text": "\n                ", "@id": "H4DD9183EFD824E00A5EC1A093DD54C9C", "@commented": "no"}]}, "#text": "\n            ", "@id": "H38E439AC4E314C7A99803CB4988FF7E9"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "by adding at the\n\t\t\t end of the subsection the following:"}, "enum": {"#tail": "\n            ", "#text": "(E)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n            ", "#text": ";\n\t\t\t\tand"}, "#tail": "\n\t\t\t\t\t", "paragraph": [{"#tail": "\n              ", "subparagraph": [{"#tail": "\n                ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "inform the\n\t\t\t\tindividual patient for whom such order is being written that a compounded drug\n\t\t\t\tis being prescribed; and"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "H36EDAAAB17184262940236F1E33D6E47", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "provide such\n\t\t\t\tpatient with a written document containing information concerning the\n\t\t\t\tavailability, safety, and production of compounded drugs."}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "HC0D1AEFE569A4160BE781E06A6A5EF2A", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "Prescriber\n\t\t\t\tnotification"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", the physician or other licensed\n\t\t\t\tpractitioner who will write such order shall\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:a"}, "#text": "Before providing a prescription order for a drug to\n\t\t\t\tbe compounded under "}, "#text": "\n                  ", "@id": "H73C976A7DED344E688F6F1C9C26CAD51"}, {"#tail": "\n                ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "confirm that the\n\t\t\t\tpatient (or the individual to whom the drug is delivered on behalf of the\n\t\t\t\tpatient) understands that the drug is a compounded drug; and"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "HDFD732F2A9C342BEBF51192C451AF97D", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "provide a written\n\t\t\t\tdocument containing the information described in\n\t\t\t\t", "internal-xref": {"@idref": "HC0D1AEFE569A4160BE781E06A6A5EF2A", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                      ", "@entity-type": "act", "#text": "subparagraph (A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:4/sp:A/cl:ii", "@proposed": "true"}, "#tail": ".", "#text": "\n                        ", "@legis-path": "(4)(A)(ii)"}}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "HFA7C3C6EA1A747D380598E990F53C450", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Confirmation by\n\t\t\t\tpharmacist"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall,\n\t\t\t\tat the time such drug is dispensed\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:a"}, "#text": "Except in the case of a compounded drug product used\n\t\t\t\tin a procedure described in\n\t\t\t\t", "internal-xref": {"@idref": "HAE2E69B954FF446080861FF536040966", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "act", "#text": "subparagraph (C)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:4/sp:C", "@proposed": "true"}, "#tail": ", a licensed pharmacist or\n\t\t\t\tlicensed physician who dispenses a compounded drug under ", "#text": "\n                      ", "@legis-path": "(4)(C)"}}, "#text": "\n                  ", "@id": "H7D36BD476F034E0D89428584F594FD78"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "inform the patient\n\t\t\t\tthat a compounded drug will be used during the procedure; and"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "H23CC51A767CF40098A598E1EF3BB2C89", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "provide such\n\t\t\t\tpatient with a written document containing the information described in\n\t\t\t\t", "internal-xref": {"@idref": "HC0D1AEFE569A4160BE781E06A6A5EF2A", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                      ", "@entity-type": "act", "#text": "subparagraph (A)(ii)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:4/sp:A/cl:ii", "@proposed": "true"}, "#tail": ".", "#text": "\n                        ", "@legis-path": "(4)(A)(ii)"}}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "H60FF7482EC2C4D638FBF9BD03F3DAF8A", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Provider\n\t\t\t\tnotification"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " will be administered to a patient for purposes of treating\n\t\t\t\tsuch patient, the health care provider shall\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:a"}, "#text": "Prior to providing a health care service that will\n\t\t\t\tbe conducted by a health care provider in a health care setting (such as a\n\t\t\t\thospital or a physician\u2019s office) and during which service a drug compounded\n\t\t\t\tunder "}, "#text": "\n                  ", "@id": "HAE2E69B954FF446080861FF536040966"}], "enum": {"#tail": "\n                ", "#text": "(4)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Notification"}, "#text": "\n                ", "@id": "H4BB90074DCE749279F60FC6BFA7DB754"}, {"#tail": "\n              ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall be\n\t\t\t\tclearly labeled as a ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:a"}, "term": {"#tail": ".", "#text": "non-FDA approved compounded drug\n\t\t\t\tproduct"}, "#text": "A drug product compounded under "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n                  ", "@id": "HCA82558ED7C54819BAD850FD9965C76B"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "shall establish, and consult with, a\n\t\t\t\ttemporary advisory committee on compounded drug product labeling requirements;\n\t\t\t\tand", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "H96CDFC33B2AD4E27BA92D640F50C0E5B", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "#text": "may establish\n\t\t\t\tdifferent labeling requirements for\u2014"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "subclause": [{"#tail": "\n                    ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "#text": "a compounded drug\n\t\t\t\tproduct intended for use by a health care provider in an office or treatment\n\t\t\t\tsetting; and"}, "enum": {"#tail": "\n                      ", "#text": "(I)"}, "@id": "HC868F7E0EC5A458C8E212140191797DA", "#text": "\n                      "}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t\t", "#text": "a compounded drug\n\t\t\t\tproduct intended for any use not described in\n\t\t\t\t", "internal-xref": {"@idref": "HC868F7E0EC5A458C8E212140191797DA", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                        ", "@entity-type": "act", "#text": "subclause (I)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:5/sp:B/cl:ii/scl:I", "@proposed": "true"}, "#tail": ".", "#text": "\n                          ", "@legis-path": "(5)(B)(ii)(I)"}}, "enum": {"#tail": "\n                      ", "#text": "(II)"}, "@id": "HC9B519FAF6DB4C1B8C2C0F5C01729ECC", "#text": "\n                      "}], "#text": "\n                    ", "@id": "H3960D0E29E854624ABBC7245F22067B6"}], "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Development of\n\t\t\t\trequirements"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "In determining the requirements for the label under\n\t\t\t\t", "internal-xref": {"@idref": "HCA82558ED7C54819BAD850FD9965C76B", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "act", "#text": "subparagraph (A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:4/sp:A", "@proposed": "true"}, "#tail": ", the ", "#text": "\n                      ", "@legis-path": "(5)(A)"}}, "#text": "\n                  ", "@id": "HFD465C438CBA4E0FA166F86D2EBEC0C9"}], "enum": {"#tail": "\n                ", "#text": "(5)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Labeling"}, "#text": "\n                ", "@id": "H28FE3F35887F4035B6244C46D7697E04"}, {"#tail": "\n              ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": ", in consultation with experts and\n\t\t\t\trepresentatives of stakeholders including pharmacies, compounding pharmacies,\n\t\t\t\tState regulators, and health care providers, shall establish a process for\n\t\t\t\tpharmacies described in ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " to register as a compounding\n\t\t\t\tpharmacy. Such registration shall be conducted through an electronic\n\t\t\t\tmethod.", "@entity-type": "act", "#text": "subsection (a)(1)(A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:A"}], "#text": "The "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "header": {"#tail": "\n                  ", "#text": "Establishment of\n\t\t\t\tprocess"}, "#text": "\n                  ", "@id": "H592456BE78264AC0A4ECDD0C48F3733A", "@commented": "no"}, {"#tail": "\n                ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "contact\n\t\t\t\tinformation for the pharmacy;"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "H4593495633B6432EBA9C70EA7A9F76C1", "#text": "\n                    "}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the State or\n\t\t\t\tStates that the pharmacy is licensed in;"}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "H4FD546BAAD634FA68FA34A52A38A8535", "#text": "\n                    "}, {"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "the methods used\n\t\t\t\tby the facility in compounding; and"}, "enum": {"#tail": "\n                    ", "#text": "(iii)"}, "@id": "H49CE4C510EA34B23B5D70CAE4DA7B2DA", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", which may include the quantity of\n\t\t\t\tproduct compounded at such pharmacy for the purpose of determining if a drug\n\t\t\t\tmanufacturing facility is inappropriately registering as a compounding\n\t\t\t\tpharmacy.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "any additional\n\t\t\t\tinformation required by the "}, "enum": {"#tail": "\n                    ", "#text": "(iv)"}, "#text": "\n                    ", "@id": "H860C34A09DB044A6A82BA631B9B04C07", "@commented": "no"}], "enum": {"#tail": "\n                  ", "#text": "(B)"}, "header": {"#tail": "\n                  ", "#text": "Registration\n\t\t\t\trequirement"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " for purposes of ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", every person who owns\n\t\t\t\tor operates a pharmacy shall submit to the ", "@entity-type": "act", "#text": "subsection (a)(1)(A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:A"}, {"#tail": ", in such time and manner\n\t\t\t\tas the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " may require\u2014", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}], "#text": "Except as provided in\n\t\t\t\t", "internal-xref": {"@idref": "HDF68737321024B5B8A14ED41E5FF7D85", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                    ", "@entity-type": "act", "#text": "subparagraph (C)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:6/sp:C", "@proposed": "true"}, "#tail": ", in order to be registered\n\t\t\t\twith the ", "#text": "\n                      ", "@legis-path": "(6)(C)"}}, "#text": "\n                  ", "@id": "HDCE9FB4CA68744F69A9D9647A37F6DC4"}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "section 510", "@value": "Federal Food, Drug, and Cosmetic Act/s:510"}, "#text": "An entity registered under this subsection\n\t\t\t\tshall not be required to submit a registration under "}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "header": {"#tail": "\n                  ", "#text": "Prohibition on\n\t\t\t\tdual registration"}, "#text": "\n                  ", "@id": "H6D094ADD923341AA9DDFA82B4B5B6ADD"}, {"#tail": "\n              ", "clause": [{"#tail": "\n                  ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "employs fewer than\n\t\t\t\t20 full-time employees (or 20 full-time equivalents); and"}, "enum": {"#tail": "\n                    ", "#text": "(i)"}, "@id": "HA1F2ADAB5EB84B4BB217CC1A701F6BBF", "#text": "\n                    "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "#text": "performs\n\t\t\t\ttraditional compounding of drug products for use in a single\n\t\t\t\tState."}, "enum": {"#tail": "\n                    ", "#text": "(ii)"}, "@id": "H428BE245D98B43228AE413FB4BE31B3F", "#text": "\n                    "}], "enum": {"#tail": "\n                  ", "#text": "(D)"}, "header": {"#tail": "\n                  ", "#text": "Exception"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " if the pharmacy\u2014", "@entity-type": "act", "#text": "subsection\n\t\t\t\t(a)(1)(A)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:a/p:1/sp:A"}, "#text": "A\n\t\t\t\tpharmacy shall be exempt from the requirement to register under "}, "#text": "\n                  ", "@id": "HDF68737321024B5B8A14ED41E5FF7D85", "@commented": "no"}], "enum": {"#tail": "\n                ", "#text": "(6)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "Registration"}, "#text": "\n                ", "@id": "H249A92A2C9134781B687CF5C48088D2F", "@commented": "no"}], "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t\t", "@id": "H8F9AA75C24C5449AA7EA71FE6D3E0C79"}, "#text": "\n            ", "@id": "HB6AEF3ECA11B4423938187796A632025"}]}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " the following:", "@entity-type": "act", "#text": "section 503A", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A"}, "#text": "by adding at the\n\t\t\t end of "}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n          ", "#text": "."}, "#tail": "\n\t\t\t\t", "subsection": [{"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(g)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Database"}, "paragraph": [{"#tail": "\n              ", "@id": "H84B64F5F93064FAF9ED1D1A85A24C340", "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish and maintain a database of\n\t\t\t\tinformation on pharmacies compounding drug products under ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " that\n\t\t\t\tare licensed in more than one State, including\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:a"}], "#text": "The "}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the minimum\n\t\t\t\tstandards for a compounding pharmacy license in each State;"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "HAD2E6DB234B54FA09B61E3317BEF7863", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " by State agencies that regulate\n\t\t\t\tpharmacies;", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "relevant\n\t\t\t\tinformation provided to the "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "H9C837886EED34B3EB9F41D1BF6E040D7", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "reliable, timely, and comprehensive data\n\t\t\t\trelated to inspections of such pharmacies, including the classification of\n\t\t\t\tactions indicated as a result of such inspections; and", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@id": "H9A4D40BFD6E743CA88ADCE2BCC07E394", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "other information\n\t\t\t\tdetermined relevant by the "}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@id": "HE219FD162787493CA69036B93C267954", "#text": "\n                  "}]}, {"#tail": "\n            ", "@id": "H90D97F246977492A86E720F4564CEE0C", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Design"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "The\n\t\t\t\tdatabase under\n\t\t\t\t", "internal-xref": {"@idref": "H84B64F5F93064FAF9ED1D1A85A24C340", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                  ", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:g/p:1", "@proposed": "true"}, "#tail": "\u2014", "#text": "\n                    ", "@legis-path": "(g)(1)"}}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", to State agencies that\n\t\t\t\tregulate pharmacies that compound drug products;", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "shall be\n\t\t\t\taccessible, as determined appropriate by the "}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "@id": "HAD8C03CC4F9941EA9B438329AFF7A02C", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to share information to ensure appropriate oversight\n\t\t\t\tof pharmacies that compound drug products;", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "shall enable\n\t\t\t\tStates and the "}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "@id": "H5E3440448CEA45F9AECC0481D23D9B66", "#text": "\n                  "}, {"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " to inform the Federal inspection and oversight of pharmacies that\n\t\t\t\tcompound drug products to ensure that issues and pharmacies identified in the\n\t\t\t\tdatabase receive appropriate oversight; and", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "shall be used by\n\t\t\t\tthe "}, "enum": {"#tail": "\n                  ", "#text": "(C)"}, "@id": "H93A1E6DD3A2149DBA5AE182B6E503E11", "#text": "\n                  "}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", to health care providers and consumers.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "shall be accessible, as determined\n\t\t\t\tappropriate by the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n                  ", "#text": "(D)"}, "@id": "H9AC389C5137F4848A4F3C8E8CA4D6A42", "#text": "\n                  "}]}], "#text": "\n              ", "@id": "HB73577339FF149C895C204A99F6E4B5C"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall, after consultation with appropriate stakeholders (including\n\t\t\t\tpharmacists, patient and public health advocacy groups, manufacturers, and\n\t\t\t\thealth care professionals), promulgate a list of active ingredients and dosage\n\t\t\t\tforms that should not be compounded, because the compounding of such active\n\t\t\t\tingredient or dosage form is reasonably likely to present a risk to public\n\t\t\t\thealth.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The\n\t\t\t\t"}, "enum": {"#tail": "\n              ", "#text": "(h)"}, "header": {"#tail": "\n              ", "#text": "Active\n\t\t\t\tingredients and dosage forms that should not be compounded"}, "#text": "\n              ", "@id": "H94AFA2F4878C43B8BE069DE47AE616FC", "@commented": "no"}, {"#tail": "\n            ", "enum": {"#tail": "\n              ", "#text": "(i)"}, "header": {"#tail": "\n\t\t\t\t\t\t\t", "#text": "Minimum\n\t\t\t\tstandards"}, "paragraph": [{"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall promulgate minimum standards for the\n\t\t\t\tsafe production of compounded drug products under this section.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The "}, "enum": {"#tail": "\n                ", "#text": "(1)"}, "header": {"#tail": "\n                ", "#text": "In\n\t\t\t\tgeneral"}, "#text": "\n                ", "@id": "H342E4DD621A54B3E8AC8601254E12739", "@commented": "no"}, {"#tail": "\n            ", "@id": "H1271A95FCA104D83B032E3B128ACACAA", "enum": {"#tail": "\n                ", "#text": "(2)"}, "header": {"#tail": "\n                ", "#text": "Contents"}, "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall each specify\u2014", "@entity-type": "act", "#text": "paragraph (1)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:i/p:1", "@proposed": "true"}, "#text": "The\n\t\t\t\tstandards under "}, "#text": "\n                ", "subparagraph": [{"#tail": "\n                ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the type of\n\t\t\t\tcompounded drug products to which they apply; and"}, "enum": {"#tail": "\n                  ", "#text": "(A)"}, "#text": "\n                  ", "@id": "HD0F34FE8A86341218377E27A17E200A9", "@commented": "no"}, {"#tail": "\n              ", "text": {"#tail": "\n\t\t\t\t\t\t\t\t", "#text": "the intended route\n\t\t\t\tof administration."}, "enum": {"#tail": "\n                  ", "#text": "(B)"}, "#text": "\n                  ", "@id": "H5D756275AB1F49F7B3D1B6C51B0372EA", "@commented": "no"}], "@commented": "no"}], "#text": "\n              ", "@id": "HB3D1D236330A4660890AAB00811EE8E5", "@commented": "no"}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall conduct a series of regional training opportunities for State\n\t\t\t\tagencies that regulate pharmacies that compound drug products. These training\n\t\t\t\topportunities shall include information on the minimum standards under\n\t\t\t\t", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": ", sample inspection protocol, and recordkeeping to facilitate the\n\t\t\t\tinclusion of State findings and inspections into the database under ", "@entity-type": "act", "#text": "subsection (i)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:i", "@proposed": "true"}, {"#tail": ".", "@entity-type": "act", "#text": "subsection\n\t\t\t\t(g)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:g", "@proposed": "true"}], "#text": "The\n\t\t\t\t"}, "enum": {"#tail": "\n              ", "#text": "(j)"}, "header": {"#tail": "\n              ", "#text": "Training"}, "#text": "\n              ", "@id": "HB2AC61D7BA5F48B5A4B849318F9872D6"}], "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t\t", "@id": "HD3AFA48283F3492CBBCD36C2ACDA74ED"}, "#text": "\n          ", "@id": "H82894338EE3248D48FB8267E8AC58E17"}], "#text": "\n        ", "@id": "H9E8DF6A4A4C04AD0A12FF578F2760045"}, {"#tail": "\n    ", "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n\t\t\t\t", "#text": "Deadlines and\n\t\t\t advisory committees"}, "paragraph": [{"#tail": "\n        ", "@id": "H86AE3FBBB33E4031A76AEAFFEB727051", "enum": {"#tail": "\n          ", "#text": "(1)"}, "header": {"#tail": "\n          ", "#text": "Deadline for\n\t\t\t issuance of regulations"}, "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t issue regulations to implement\u2014", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "#text": "Not later than 18 months after the date\n\t\t\t of enactment of this Act, the "}, "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " and\n\t\t\t ", "@entity-type": "act", "#text": "paragraphs (4)", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:4"}, {"#tail": ", as added by\n\t\t\t ", "@entity-type": "act", "#text": "(5) of section 503A(b) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:b/p:5"}, {"#tail": "; and", "@entity-type": "act", "#text": "subsection (a)", "@value": "Supporting Access to Formulated and Effective Compounded Drugs Act of 2013/s:2/ss:a", "@proposed": "true"}], "#text": "\n              "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "@id": "H146EBE5B0B7B4499B0509159F24C4540", "#text": "\n            "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "subsection (g) of\n\t\t\t section 503A of such Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:g", "@proposed": "true"}, "#text": "\n              "}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "@id": "HDE6957F29CB34FABBB0133A8B1D74945", "#text": "\n            "}]}, {"#tail": "\n        ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall establish an advisory committee on\n\t\t\t labeling (as defined in ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "#text": "The\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": ") of compounded drug products and shall consult such committee\n\t\t\t in the development of the regulations under\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t (", "@entity-type": "act", "#text": "section 201 of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:201"}, "@entity-type": "law-citation", "#text": "\n                ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n                ", "@entity-type": "uscode", "#text": "21 U.S.C. 321", "@value": "usc/21/321"}, "@parsable-cite": "usc/21/321", "#text": "\n                  ", "@legal-doc": "usc"}}, "internal-xref": {"@idref": "H146EBE5B0B7B4499B0509159F24C4540", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "act", "#text": "paragraph (1)(A)", "@value": "Supporting Access to Formulated and Effective Compounded Drugs Act of 2013/s:2/ss:b/p:1/sp:A", "@proposed": "true"}, "#tail": ".", "#text": "\n                ", "@legis-path": "2.(b)(1)(A)"}}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "header": {"#tail": "\n            ", "#text": "Establishment"}, "#text": "\n            ", "@id": "H28826575FD2B4348AA0A400D823687F9"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "The\n\t\t\t advisory committee shall include representatives of patients or consumers,\n\t\t\t health care providers, compounding pharmacies, State agencies that regulate\n\t\t\t compounding pharmacies, and at least one member with expertise on clearly\n\t\t\t communicating information in such labeling of drugs."}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "header": {"#tail": "\n            ", "#text": "Membership"}, "#text": "\n            ", "@id": "H98EB692A47F0411F9AFC7A14BAA56479"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "The\n\t\t\t advisory committee shall hold an initial meeting not later than 6 months after\n\t\t\t the date of enactment of this Act."}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "header": {"#tail": "\n            ", "#text": "Meetings"}, "#text": "\n            ", "@id": "HC2DAF657496842BBB85E4E00B26B6205"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": "\n\t\t\t recommendations on the regulations under\n\t\t\t ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": ".", "@entity-type": "act", "#text": "section 503A of\n\t\t\t the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A"}], "#text": "Not\n\t\t\t later than 12 months after the date of enactment of this Act, the advisory\n\t\t\t committee shall submit to the ", "internal-xref": {"@idref": "H146EBE5B0B7B4499B0509159F24C4540", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "act", "#text": "paragraph (1)(A)", "@value": "Supporting Access to Formulated and Effective Compounded Drugs Act of 2013/s:2/ss:b/p:1/sp:A", "@proposed": "true"}, "#tail": ", including\n\t\t\t recommendations on the type of information and language that should be included\n\t\t\t on the labels of drug products that are compounded pursuant to ", "#text": "\n                ", "@legis-path": "2.(b)(1)(A)"}}, "enum": {"#tail": "\n            ", "#text": "(D)"}, "header": {"#tail": "\n            ", "#text": "Recommendations"}, "#text": "\n            ", "@id": "H1022F18FC9B2475881158BA65CD95B3D"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "The\n\t\t\t advisory committee under this subparagraph shall terminate upon the submission\n\t\t\t of the recommendations under\n\t\t\t ", "internal-xref": {"@idref": "H1022F18FC9B2475881158BA65CD95B3D", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "act", "#text": "subparagraph (D)", "@value": "Supporting Access to Formulated and Effective Compounded Drugs Act of 2013/s:2/ss:b/p:2/sp:D", "@proposed": "true"}, "#tail": ".", "#text": "\n                ", "@legis-path": "2.(b)(2)(D)"}}, "enum": {"#tail": "\n            ", "#text": "(E)"}, "header": {"#tail": "\n            ", "#text": "Termination"}, "#text": "\n            ", "@id": "H566BFDC65BA84FD588962C668229D1DD"}], "enum": {"#tail": "\n          ", "#text": "(2)"}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Labeling\n\t\t\t advisory committee"}, "#text": "\n          ", "@id": "H8375EFC8518B47F281C59394C034EAD8"}, {"#tail": "\n        ", "@id": "H1482CF586F3E4E459146C56609F2C0B0", "enum": {"#tail": "\n          ", "#text": "(3)"}, "header": {"#tail": "\n\t\t\t\t\t", "#text": "Database\n\t\t\t advisory committee"}, "@display-inline": "no-display-inline", "#text": "\n          ", "subparagraph": [{"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall establish an advisory committee on\n\t\t\t the database described in ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, {"#tail": ", as added by ", "@entity-type": "act", "#text": "section 503A(g) of the Federal Food, Drug, and\n\t\t\t Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A/ss:g", "@proposed": "true"}, {"#tail": ", and shall consult such committee in\n\t\t\t the development of the regulations under\n\t\t\t ", "@entity-type": "act", "#text": "subsection (a)", "@value": "Supporting Access to Formulated and Effective Compounded Drugs Act of 2013/s:2/ss:a", "@proposed": "true"}, {"@proposed": "true", "#tail": ".", "@entity-type": "act", "@value": "Supporting Access to Formulated and Effective Compounded Drugs Act of 2013/s:2/ss:b/p:1/sp:B", "#text": "\n                ", "internal-xref": {"@idref": "HDE6957F29CB34FABBB0133A8B1D74945", "#tail": "\n              ", "#text": "paragraph (1)(B)", "@legis-path": "2.(b)(1)(B)"}}], "#text": "The\n\t\t\t "}, "enum": {"#tail": "\n            ", "#text": "(A)"}, "header": {"#tail": "\n            ", "#text": "Establishment"}, "#text": "\n            ", "@id": "H19695D587735470399FBEC0D933928F2"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "The advisory committee shall include\n\t\t\t representatives of patients or consumers, health care providers, compounding\n\t\t\t pharmacies, State agencies that regulate compounding pharmacies, and\n\t\t\t information technology experts.", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(B)"}, "header": {"#tail": "\n            ", "#text": "Membership"}, "#text": "\n            ", "@id": "H96EAE70A45404B32B9A8B0790FCE04C1"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "The\n\t\t\t advisory committee shall hold an initial meeting not later than 6 months after\n\t\t\t the date of enactment of this Act."}, "enum": {"#tail": "\n            ", "#text": "(C)"}, "header": {"#tail": "\n            ", "#text": "Meetings"}, "#text": "\n            ", "@id": "HED1C93BF186A4BE98EE7ACA817E54581"}, {"#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n\t\t\t recommendations on the regulations under\n\t\t\t ", "@entity-type": "federal-body", "#text": "Secretary of Health and Human Services", "@entity-id": "7500"}, "#text": "Not\n\t\t\t later than 12 months after the date of enactment of this Act, the advisory\n\t\t\t committee shall submit to the ", "internal-xref": {"@idref": "HDE6957F29CB34FABBB0133A8B1D74945", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ".", "@entity-type": "act", "#text": "paragraph (1)(B)", "@value": "Supporting Access to Formulated and Effective Compounded Drugs Act of 2013/s:2/ss:b/p:1/sp:B", "@proposed": "true"}, "#tail": "\n            ", "#text": "\n                ", "@legis-path": "2.(b)(1)(B)"}}, "enum": {"#tail": "\n            ", "#text": "(D)"}, "header": {"#tail": "\n            ", "#text": "Recommendations"}, "#text": "\n            ", "@id": "H458DD63BD7434332A2F4B9FBB0CD55B9"}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t\t", "#text": "The\n\t\t\t advisory committee under this subparagraph shall terminate upon the submission\n\t\t\t of the recommendations under\n\t\t\t ", "internal-xref": {"@idref": "H458DD63BD7434332A2F4B9FBB0CD55B9", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "act", "#text": "subparagraph (D)", "@value": "Supporting Access to Formulated and Effective Compounded Drugs Act of 2013/s:2/ss:b/p:3/sp:D", "@proposed": "true"}, "#tail": ".", "#text": "\n                ", "@legis-path": "2.(b)(3)(D)"}}, "enum": {"#tail": "\n            ", "#text": "(E)"}, "header": {"#tail": "\n            ", "#text": "Termination"}, "#text": "\n            ", "@id": "H6140B8778560472CB5779789823AEDB4"}]}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t convene the Advisory Committee on Pharmacy Compounding as appropriate to\n\t\t\t consider issues related to the safety and availability of compounded drug\n\t\t\t products.", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, "#text": "The "}, "enum": {"#tail": "\n          ", "#text": "(4)"}, "header": {"#tail": "\n          ", "#text": "Permanent\n\t\t\t advisory committee on pharmacy compounding"}, "#text": "\n          ", "@id": "HD93043010B6E42CBA1E453C6EC3E5C46"}], "#text": "\n        ", "@id": "H57C5CCCA61AE4183A795B03544A27658"}], "#text": "\n      ", "@id": "H846C6CD243954378B6C53511A05A9D59"}, {"@section-type": "subsequent-section", "#tail": "\n    ", "enum": {"#tail": "\n      ", "#text": "3."}, "header": {"#tail": "\n\t\t\t", "#text": "Reports and\n\t\t\t studies"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit to the ", "@entity-type": "federal-body", "#text": "Secretary of Health and\n\t\t\t Human Services", "@entity-id": "7500"}, {"#tail": " a report on the status of the\n\t\t\t implementation of the requirements of this Act, and the amendments made by this\n\t\t\t Act.", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "Not later than 6 months after the date of enactment of\n\t\t\t this Act, and at the end of each succeeding 6-month period that ends before the\n\t\t\t 25th month after the date of enactment of this Act, the "}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Biannual\n\t\t\t reports"}, "#text": "\n        ", "@id": "H96B975115C204193B958F81CF016AC53"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit\n\t\t\t to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " a report that contains\u2014", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "Not later than\n\t\t\t 12 months after the date of enactment of this Act, the ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Third-Party\n\t\t\t Accreditation"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "a\n\t\t\t review of the standards used by organizations that provide accreditation to\n\t\t\t compounding pharmacies; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H2571260D627840A4B0CD30E3BF5AE4C7", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "an evaluation of\n\t\t\t the effectiveness of such standards in ensuring the production of safe and\n\t\t\t effective compounded drug products."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "HC4A4D1D58AF04CAAAA648EC1CA2FBB87", "#text": "\n          "}], "#text": "\n        ", "@id": "H2D35F6A1200D410387A7D172410E37F8"}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " shall submit to the ", "@entity-type": "federal-body", "#text": "Secretary", "@entity-id": "7500"}, {"#tail": " a report that\n\t\t\t contains\u2014", "@entity-type": "federal-body", "#text": "Congress", "@entity-id": "0001"}], "#text": "Not later than 18 months after the date of\n\t\t\t enactment of this Act, the "}, "enum": {"#tail": "\n        ", "#text": "(c)"}, "header": {"#tail": "\n        ", "#text": "Structure of\n\t\t\t State oversight"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "a\n\t\t\t review of the models used by States to structure their oversight of pharmacies\n\t\t\t that compound drug products, including the structure of the agency or office\n\t\t\t responsible for oversight and its relationship with the industry that it\n\t\t\t regulates; and"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "HA1D0FF63E9984260BD990E464B8F3CCE", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "consideration of\n\t\t\t how the structure and relationship of State regulators may impact the\n\t\t\t development and enforcement of regulations to ensure safe compounded drug\n\t\t\t products."}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "H458C52321DC84AE39B8D9C755C43F4FE", "#text": "\n          "}], "#text": "\n        ", "@id": "HC1220B56AD6A48BEB509B7347B862D8F"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " shall\n\t\t\t review\u2014", "@entity-type": "federal-body", "#text": "Comptroller General of the United States", "@entity-id": "0500"}, "#text": "The "}, "enum": {"#tail": "\n        ", "#text": "(d)"}, "header": {"#tail": "\n        ", "#text": "GAO\n\t\t\t report"}, "paragraph": [{"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "the extent to which Federal health care\n\t\t\t programs (as such term is defined in ", "{http://namespaces.cato.org/catoxml}entity": [{"#tail": ") ensure that compounded drug products which are paid\n\t\t\t for by such programs are compounded in facilities that comply with the\n\t\t\t requirements of the ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "section 1128B(f) of the Social Security\n\t\t\t Act", "@value": "Social Security Act/s:1128B/ss:f"}, "@entity-type": "law-citation", "#text": "\n              ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n              ", "@entity-type": "uscode", "#text": "42 U.S.C. 1320a\u20137b", "@value": "usc/42/1320a\u20137b"}, "@parsable-cite": "usc/42/1320a-7b", "#text": "\n                ", "@legal-doc": "usc"}}, {"#tail": ";", "{http://namespaces.cato.org/catoxml}entity-ref": [{"#tail": " (", "@entity-type": "act", "#text": "Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act"}, {"#tail": ")", "@entity-type": "uscode", "#text": "21 U.S.C. 301 et\n\t\t\t seq.", "@value": "usc/21/301/etseq"}], "@entity-type": "law-citation", "#text": "\n              "}], "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n          ", "#text": "(1)"}, "@id": "H723DA31B4E764218A9967EA0C4C01148", "#text": "\n          "}, {"#tail": "\n        ", "text": {"#tail": "\n\t\t\t\t", "#text": "whether the\n\t\t\t reimbursement rates for compounded drug products under such Federal health care\n\t\t\t programs are appropriate, taking into consideration the cost of production of\n\t\t\t such compounded drug products; and"}, "enum": {"#tail": "\n          ", "#text": "(2)"}, "@id": "HA5ABDA8F12F64CE1A8932765055CB9CD", "#text": "\n          "}, {"#tail": "\n      ", "text": {"#tail": "\n\t\t\t\t", "#text": "whether such\n\t\t\t Federal health care programs encourage the use of compounded drug products in\n\t\t\t place of otherwise available lawfully marketed drug products."}, "enum": {"#tail": "\n          ", "#text": "(3)"}, "@id": "H6F82C5ED17B1459CBF15AF34357A87E7", "#text": "\n          "}], "#text": "\n        ", "@id": "HC76333955A1C452E8EE45537607FB85B"}], "@display-inline": "no-display-inline", "#text": "\n      ", "@id": "H1823EA1FFB8545C4A865AA89C30BBEC5"}, {"#tail": "\n  ", "enum": {"#tail": "\n      ", "#text": "4."}, "header": {"#tail": "\n\t\t\t", "#text": "Prohibitions and\n\t\t\t penalties"}, "subsection": [{"#tail": "\n      ", "text": {"#tail": "\n\t\t\t", "quote": [{"#tail": " before ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ",", "@entity-type": "act", "#text": "503A", "@value": "Federal Food, Drug, and Cosmetic Act/s:503A"}, "#text": "\n            "}, {"#tail": ".", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ",", "@entity-type": "act", "#text": "505", "@value": "Federal Food, Drug, and Cosmetic Act/s:505"}, "#text": "\n            "}], "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is amended by inserting\n\t\t\t ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section 301(d) of the Federal Food,\n\t\t\t Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:301/ss:d"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 331(d)", "@value": "usc/21/331/d"}, "@parsable-cite": "usc/21/331", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(a)"}, "header": {"#tail": "\n        ", "#text": "Prohibition of\n\t\t\t violations of section 503A"}, "#text": "\n        ", "@id": "H93FDA82D7BAE4AA591F86D43450AD6AA"}, {"#tail": "\n    ", "text": {"#tail": "\n\t\t\t\t", "#text": "\n          ", "{http://namespaces.cato.org/catoxml}entity": {"#tail": " is\n\t\t\t amended by adding at the end the following:", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": " (", "@entity-type": "act", "#text": "Section\n\t\t\t 303(b) of the Federal Food, Drug, and Cosmetic Act", "@value": "Federal Food, Drug, and Cosmetic Act/s:303/ss:b"}, "@entity-type": "law-citation", "#text": "\n            ", "external-xref": {"#tail": ")", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": "\n            ", "@entity-type": "uscode", "#text": "21 U.S.C. 333(b)", "@value": "usc/21/333/b"}, "@parsable-cite": "usc/21/333", "#text": "\n              ", "@legal-doc": "usc"}}}, "enum": {"#tail": "\n        ", "#text": "(b)"}, "header": {"#tail": "\n        ", "#text": "Penalties"}, "quoted-block": {"@style": "OLC", "after-quoted-block": {"#tail": "\n        ", "#text": "."}, "#tail": "\n\t\t\t", "paragraph": {"continuation-text": {"#tail": "\n          ", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", imprisoned for not more than 10\n\t\t\t\tyears, or\n\t\t\t\tboth.", "@entity-type": "uscode", "#text": "title 18, United States Code", "@value": "usc/18"}, "@continuation-text-level": "paragraph", "#text": "shall be\n\t\t\t\tfined under "}, "#tail": "\n          ", "text": {"#tail": "\n\t\t\t\t\t\t", "{http://namespaces.cato.org/catoxml}entity-ref": {"#tail": ", any person\n\t\t\t\twho violates section 301(d) with respect to any compounded drug product\u2014", "@entity-type": "act", "#text": "subsection (a)", "@value": "Federal Food, Drug, and Cosmetic Act/s:303/ss:a"}, "#text": "Notwithstanding ", "@display-inline": "yes-display-inline"}, "enum": {"#tail": "\n            ", "#text": "(8)"}, "#text": "\n            ", "@id": "H9D3E5D57A91D4F5785E9ABF53FB2CB04", "subparagraph": [{"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "knowingly and\n\t\t\t\tintentionally to defraud or mislead; or"}, "enum": {"#tail": "\n              ", "#text": "(A)"}, "@id": "H4AC5B465288842E3801F240E2F18E2CF", "#text": "\n              "}, {"#tail": "\n            ", "text": {"#tail": "\n\t\t\t\t\t\t", "#text": "with conscious or\n\t\t\t\treckless disregard of a risk of death or serious bodily injury,"}, "enum": {"#tail": "\n              ", "#text": "(B)"}, "@id": "HCCA612AEED534FBD8DED3A80913C4CEA", "#text": "\n              "}]}, "@display-inline": "no-display-inline", "#text": "\n\t\t\t\t\t", "@id": "HB7BBDE33C4134A1AA7EFD40BEDE7501C"}, "#text": "\n        ", "@id": "H2077CA2A1E704D97AC041D57E0D66B8A"}], "#text": "\n      ", "@id": "H17DB6680C63A4F0AA9FAE0FB7CF926A6"}], "#text": "\n\t\t", "@id": "HAC2A03986CCF4266851FA1E861F44F08"}, "metadata": {"#tail": "\n", "dublinCore": {"{http://purl.org/dc/elements/1.1/}date": {"#tail": "\n", "#text": "2013-08-02"}, "{http://purl.org/dc/elements/1.1/}format": {"#tail": "\n", "#text": "text/xml"}, "{http://purl.org/dc/elements/1.1/}language": {"#tail": "\n", "#text": "EN"}, "#tail": "\n", "{http://purl.org/dc/elements/1.1/}title": {"#tail": "\n", "#text": "113 HR 3019 IH: Supporting Access to Formulated and Effective Compounded Drugs Act of 2013"}, "{http://purl.org/dc/elements/1.1/}rights": {"#tail": "\n", "#text": "Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain."}, "{http://purl.org/dc/elements/1.1/}publisher": {"#tail": "\n", "#text": "U.S. House of Representatives"}, "#text": "\n"}, "#text": "\n"}}}